Glenmark Pharmaceuticals restricts trading for insiders ahead of Q2 2026 results Back
<p>Glenmark Pharmaceuticals Limited will close its trading window for designated persons, including directors, key managerial personnel, and immediate relatives, starting October 1, 2026, and continuing until the declaration of the company’s unaudited financial results for the second quarter ended September 30, 2026, and forty-eight hours thereafter.</p>